Since GLP-1 medications already slow digestion, these compounds amplify discomfort significantly
Patients should be monitored for treatment response through serial measurements of weight, waist circumference, glycemic parameters, and lipid profiles
Regarding medication management, for patients with clinical cardiovascular disease, a sodiumglucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended
The molecules compatibility with prefilled pens and auto-injectors further supports efficient distribution through home delivery channels
GLP-1 medications prescribed through Rivas telehealth Your provider determines the right medication at your initial evaluation
It has been shown that VEGFR2 is associated with Cav-1 and located in endothelial caveolae